|  |
| Kaiser study results on ranibizumab and bevacizumab
| A Kaiser Permanents Southern California study published in this month?s Ophthalmology, the journal of the American Academy of Ophthalmology, compares ranibizumab (Lucentis) and bevacizumab (Avastin) and found them to be equally effective in halting vision loss. | | | First ever sham-controlled study of radiation therapy for wet AMD initiated by Oraya Therapeutics
| | )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). | | | Visudyne evaluation indicates positive results
| | Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc. | | | Gene genie collaboration
| | A new collaboration between Oxford BioMedica and Sanofi-Aventis is to develop and commercialise gene therapy treatments for retinal degenerative diseases such as Stargardt disease, the form of early-onset macular degeneration and Usher syndrome, a relatively rare genetic disease where sufferers are born deaf and lose vision within the first 10 years of life. | | | Treating wet AMD with radiation
| | A single procedure may be as effective as repeated anti-VEGF injections claims Timothy L. Jackson. | | | The IOL-VIP system: restoring sight to AMD patients
| | Dr José Luis Menezo looks at improving the visual acuity of patients with age-related macular degeneration (AMD) using an IOL-Vip system. | | | Eye drops: a breakthrough in dry AMD treatment?
| | Paul Sternberg assesses the new approaches and exciting pipeline of potential dry AMD treatments. | | | Retina 2007
| | Take a look at what happened in the Retina field in 2007 and what exciting developments are round the corner in 2008. | | | Experience with Avastin in a UK clinic
| | A UK team reports how they achieved significant reductions in macular thickness by using intravitreal bevacizumab. | |  MORE ARTICLES
|
| |
| Implantable telescope finally gets FDA approval
| | VisionCare&#;s implantable telescope for end-stage AMD has finally been given FDA approval. The device, discussed in depth in Ophthalmology Times Europe July 2007, was given CE approval three years ago but has subsequently been undergoing rigorous clinical trials in the United States. | | | IRay stereotactic radiotherapy system gets European CE mark
| | Oraya Therapeutics has been granted the CE mark for its IRay system, which its researchers say can deliver low-energy X-rays to treat wet AMD. | | | First ever sham-controlled study of radiation therapy for wet AMD initiated by Oraya Therapeutics
| | )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). | | | Cancer drug no different in effectiveness as gold standard treatment for macular degeneration
| | Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). | | | Early AMD associated with coronary heart disease
| | The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease. | | | AMD prediction a step closer using nature or nuture variables
| | Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables. | | | Dr Ambati wins 2010 ARVO award
| | Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO). | | | AMD biological marker discovered
| | A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky. | | | Question mark over Novartis combination therapy
| | The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences. | | | MORE ARTICLES
|
| |
| |
| |
| Premium IOL options
| | For compromised, and potentially compromised eyes. | | | A new method for easier enclavation of iris-claw IOLs
| | The VacuFix technique has been introduced to fix the Artisan and Artiflex IOLs in a fast, precise and reproducible way. | |
| Do personality characteristics impact multifocal IOL patient satisfaction
| | First answers from the Happy Patient Project | | | Eyes on Oman
| More than 150 participants from 27 countries attended this year's SCHWIND User Meeting in Muscat, Oman. | | | Local anaesthesia for cataract surgery
| | A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery. | | | New approach to presbyopia treament
| | This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia. | | | Technique intra-operative findings and postoperative regimen
| | Technique intra-operative findings and postoperative regimen | | | Schwind PresbyMAX treats presbyopia with excimer surgery
| | Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited. | | | Cataract surgery in patients with pre-existing AMD: Risks and Benefits
| | Cataract surgery in patients with pre-existing AMD: Risks and Benefits | | | MORE ARTICLES
|
| |
| |
| Local anaesthesia for cataract surgery
| | A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery. | | | Ketolorac tromethamine should be available in September
| | Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced. | | | Researchers uncover genetic link to age-related cataracts
| | Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | Post cataract surgery pain treatment gets thumbs up
| | ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA. | | | Phacoemulsification fluidics characterized by new lab methods
| | Implementation of novel techniques to analyze the fluidic signature of phacoemulsification performed using different ultrasound modalities and phaco tips is providing important insights that will be helpful for improving the efficiency and safety of lens removal surgery. | | | Cataract surgery pipeline
| | The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month. | | | IOL receives further $40 million investment
| | Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe. | | | Managing post-PRK discomfort
| | When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery. | | | MORE ARTICLES
|
| |
| |
| |
| Dry eye diagnostic coming to a clinic near you
| | OcuSense, makers of the innovative TearLab Osmolarity System for the diagnosis of dry eye, announced the signing of multi-year agreements with four distributors in five EU countries, for the exclusive distribution of the TearLab system. | | | It's all changing at Zeiss
| | Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with CEO, Dr Michael Kaschke about the challenges that he faces in an ever evolving market. | | | Volk launches high resolution wide field lens
| | Volk Optical has launched the H-R Wide Field Laser Lens, a pan-retinal lens intended for diagnosis and PRP laser treatment. | | | Haag-Streit showcases comprehensive new optical biometer
| | Haag-Streit has taken the opportunity of the ESCRS meeting to unveil its innovative non-contact optical biometer, the LENSTAR LS900. | | | Seiler vs Holladay: the presbyopia debate
| | The search for a presbyopic treatment that is universally effective and universally applicable is viewed in the industry and the profession as the holy grail because of the number of people in the presbyopic age group today. | | | Moria introduces single-use cataract instruments
| | The "One" range of single-use ophthalmic instruments has been introduced by Moria. The range comprises instruments commonly used during cataract surgery; instruments are available individually, or as part of a custom pack. | | | Femtosecond to fully replace microkeratome
| | The age of microkeratomes is coming to an end as femtosecond lasers come of age. That's the chief conclusion drawn by Dr Gunther Grabner, professor of ophthalmology at the Paracelsus University of Salzburg, in a survey on the advantages and limitations of femtosecond lasers. | | | Oertli proud of new 1.6 mm tip
| | Oertli proudly showcased their new product that enables coaxial microincision cataract surgery through 1.6 mm: the CO-MICS 2 tip is fully compatible with the firm's existing OS3, SwissTech and CataRhex platforms. | | | Femtosecond gets thumbs up from Pallikaris
| | Femtosecond lasers provide a safe and effective way to create corneal flaps and tunnels, explained Professor Ionannis Pallikaris. | | | MORE ARTICLES
|
| |
| Berlin Beckons
| | Join OTE in booth BL10 at this year's ESCRS congress | | | Thank you!
| | Although we have always received a steady stream of feedback from readers, contributors and industry, never have we been bombarded by so many compliments in such a short space of time as at two recent conferences. | | | What do you want to see in OTE in 2009?
| | Fill in OTE's online readership survey for the chance to win €500 Marriott hotel vouchers. | | | The industry's evolving, so are we
| | Sometimes I sit back and think about how this magazine has evolved over the years and, on a more regular basis, I think about where we can go from here. | | | Micro innovations
| | In technological terms, when a word is prefixed by 'micro' you come to expect that word to signify some form of technological innovation or advance. In ophthalmology, the word 'microincision' represents significant advancement, particularly in the fields of cataract and vitreoretinal surgery. | | | World Glaucoma Day 2008: uniting to make a difference
| | The lack of public knowledge about glaucoma surprises me. Although pretty much everybody has heard of it, little is generally known other than the fact that it affects the eye. | | | LASIK: some still in the dark
| | I recently attended a party where I was drawn into a conversation by some people who had one thing in common – LASIK. Somebody amongst the group had undergone the procedure six years ago (incidentally, that was my sister) whilst another underwent wavefront-guided LASIK just weeks prior. Each of the four people had a story to tell about their experience with the procedure but, overall, each claimed they were happy with the end result. | | | Tempted by a free trip for two?
| | Tempted? | | | We invite you to have your say
| | When we launched Ophthalmology Times Europe (OTE) two years ago, our aim was always to provide a forum for ophthalmologists to communicate their knowledge, discoveries, experience and opinions. This aim has not changed. However, with the industry evolving at such a dramatic rate, it is difficult to convey the views and opinions of everyone who wants to be heard in our print publication. Help is at hand. | | | MORE ARTICLES
|
| |
| |
| Safe and effective barrier against contamination during TSCPC
| | Using a sterile, disposable barrier for the G-probe transsceleral cyclophotocoagulation (TSCPC) device is a safe and effective method of preventing contamination in consecutive patients. | | | Trial compares glaucoma implants
| | Baerveldt device showed better outcomes but required more interventions then Ahmed valve. | | | Diverse factors affect management
| | Ever-widening knowledge base proves that there's more to it than controlling IOPs. | | | Stability a strength of filtration device
| | Performance compares favourably with trabeculectomy, in physician's experience | | | Glaucoma innovation for end of 2010
| | The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010 | | | World Glaucoma Day
| | Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society. | | | Innovative glaucoma research award
| | The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon. | | | New study demonstrates potential for improving glaucoma diagnosis across Europe
| | Research claims that imaging devices can effectively support ophthalmologists with glaucoma diagnosis | | | Alcon acquires Optonol
| | Alcon acquires Optinol and enters glaucoma surgical market. | | | MORE ARTICLES
|
| |
| |
| Review of the year 2010
| | A review of the year in cataract & refractive, retina and glaucoma. Shows three industry experts view on their highs of the year and the changes they've experienced as well as what the future holds for 2011 | | | Two does become one
| | We report on the first cataract and refractive femtosecond laser | |
| Mixing multifocal IOLs associated with high patient satisfaction
| | Using both diffractive and refractive IOLs in fellow eyes can result in excellent outcomes | | | IOL delivers on visual quality, acuity
| | Aberration-free optic | | | Novel scleral lens proves cost-effective
| | In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P). | | | 60 years of pioneering IOL innovation
| | Rayner Intraocular Lens Limited, has marked a milestone with a celebration to honour the 60th anniversary of the implantation of the first intraocular lens (IOL) in a patient. The late Sir Harold Ridley implanted the first IOL on 29 November 1949 at St. Thomas Hospital in London. Due to the controversial nature of the surgery, this first surgery was conducted in almost total secrecy. | | | Phakic IOLs
| | Look at some of the Phakic IOLs that have been making a name for themselves in Europe. | | | Accommodating IOLs
| | Accommodating IOLs are making a splash in Europe - why don't you take a closer look at some of them? | | | Multifocal IOLs
| | Have a closer look at some of the multifocal IOLs available in Europe. | | | MORE ARTICLES
|
| |
| Point of care tear film test simplifies dry eye management
| | Diagnosing and managing dry eye patients can be challenging. Here Dr Philipp Steven looks at a new way of treating tear film osmolarity, the TearLab Osmolarity System, which he believes could dramatically simplify the process. | | | Clinical improvement in adenoviral conjunctivitis model
| | Foresight Biotherapeutics, Inc. has announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis. | | | Novagali technologies allow greater drug access to the posterior of the eye
| | According to research analysts it is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers. | | | Liquid ocular bandage launched in Europe
| | BD OcuSeal Liquid Ocular Bandage, a fully synthetic protective barrier to be used for post-surgical, post-traumatic and non-traumatic ocular conditions, has been launched in Europe by BD Medical?Ophthalmic Systems. | | | Retisert implant in sympathetic ophthalmia
| | The fluocinolone acetonide (Retisert; Bausch & Lomb) surgical implant can prevent blindness in cases of sympathetic ophthalmia (SO), according to research at the University of Iowa, US. | | | Link between skin cancer and eye cancer
| | There is an association between uveal and a variety of skin melanomas, according to study results published in the March issue of Ophthalmology. | | | Uveitis study enters Phase IIa
| | ESBATech AG, a developer of antibody fragment therapeutics, has initiated a Phase IIa study in patients with acute anterior uveitis, designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105. | | | Causes of infectious scleritis
| | Fungus and microbial infection are the most common causes of infectious scleritis, according to study conclusions published in the February issue of Eye. | | | Anti-inflammatory enters Phase I/II
| | ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer. | | | MORE ARTICLES
|
| |
| Open your mind to a new philosophy
| | Didier Ducournau talks about the development and growth of the EVRS and on his personal vision for vitreoretinal surgeons. | |
| The Italian pioneers
| | Surgeons should not feel ashamed if they only manage to see a few patients, devotion to the patient and then to your practice is of paramount importance. Then, and only then, will you be doing your job well. | | | European Society of Ophthalmology: the first 50 years
| | Since its inception in 1956, the European Society of Ophthalmology (SOE) has grown from a small entity into a conglomerate of national ophthalmological societies from all 40 European countries, representing more than 40,000 European ophthalmologists. We speak with President Zdenek Gregor about the changing face of the society, the importance of collaboration and the way the society has adapted to an ever-evolving Europe. | | | Learning to work together
| | 1991 witnessed the birth of the European Society of Cataract and Refractive Surgeons (ESCRS); a new kind of society aimed at unifying specialists and societies across a number of disciplines throughout the continent. Society President, Professor Marie José Tassignon talks to OTE about her vision for the future. | | | MORE ARTICLES
|
| |
| |
| Dear Editor
| | In answer to the question: "What specifically makes SLT different
from ALT in its action?" we offer the following response: | | | An African expedition
| | I embarked on a memorable trip to Africa recently and, along with a wonderful team of skilled ophthalmologists and nurses, we set up two eye camps in Namibia and Zambia. Our mission was to study corneal thickness in native Africans so that we could, in the future, establish the relationship between corneal thickness and glaucoma in this population. | | | MORE ARTICLES
|
| |
| Highlights from AAO 2007
| | Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA. | | | Highlights from the ESCRS Congress 2007
| | Read Ophthalmology Times Europe's extensive coverage from the 2007 annual meeting in Stockholm, Sweden. | | |
IGS 2007 Meeting Highlights
| | Athens played host to the sixth annual International Glaucoma Society (IGS) congress, which ran from 28-31 March. Attended by more than 2,650 participants from around the world, the meeting earned the title of the most attended international glaucoma meeting ever held. | | | Meeting highlights from the AAO annual congress 2006, Las Vegas, 11-14 November
| | More prospective studies are needed to evaluate the role of diurnal and long-term intraocular pressure (IOP) function in glaucoma development and progression, according to Felipe A. Medeiros, MD, PhD, assistant professor of ophthalmology, University of California at San Diego, USA, speaking at the glaucoma subspecialty session. | | | Parameters for defining quality of vision
| | According to Oliver Findl, it is becoming increasingly important to use a wider variety of parameters to assess visual quality after cataract surgery in order to gain a better understanding of patient's day-to-day experiences. | | | Wavelight announces two IOL approvals
| | Wavelight has announced the receipt of two regulatory approvals for its intraocular lenses (IOLs), thus expanding its intraocular product range. | | | Levofloxacin should be the first choice for antibacterial prophylaxis
| | Levofloxacin 0.5% eye drops should be the first choice for antibacterial prophylaxis and treatment, according to Professor P. Asbell of the Mount Sinai School of Medicine, USA. | | | Foldable toric IOL safe and effective in high astigmatism
| | According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery. | | | MICS has made very little impact on US and EU surgeon practice
| | Microincision cataract surgery (MICS), hailed to be the next big development in cataract surgery, has not had the expected impact on surgeon's practice, David Leaming revealed, whilst detailing the results of his most recent survey on cataract surgery practice in Europe and the US. | | | MORE ARTICLES
|
| |
| |
| |
| Product Profiles
| | A round up of new products | | | Product Profiles
| | A round up of new products | | | IQ 577 laser system now available to doctors
| | Iridex has commenced shipment of its IQ 577 laser systems which is designed to treat vision-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma. | | | A comparison of six OCT devices
| | In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer
| | NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data. | | | Ketolorac tromethamine should be available in September
| | Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced. | | | Implant with potential to permanently treat glaucoma
| | OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. | | | Post cataract surgery pain treatment gets thumbs up
| | ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA. | | | MORE ARTICLES
|
| |
| Inhibiting and regressing corneal neovascularisation
| | Interim results from a Phase II study by Gene Signal suggest that antisense oligonucleotide GS-101 is safe and effective at inhibiting abnormal corneal new blood vessel growth. | | | Glaucoma related to selenium levels
| | The pathology of glaucoma is likely to be related to the presence and levels of selenium, according to the results of a study published in the August issue of the British Journal of Ophthalmology. | | | The brain predicts what moving eyes will see
| | A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene. | | | Lowering levels of arginase may halt progression of diabetic retinopathy
| | High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA. | | | Researchers uncover genetic link to age-related cataracts
| | Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | When can an eye growth transform into melanoma?
| | According to a report in the August issue of Archives of Ophthalmology, there are eight factors that may predict whether a choroidal nevus-a benign, flat, pigmented growth inside the eye and beneath the retina-may develop into melanoma. | | | Implant with potential to permanently treat glaucoma
| | OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. | | | Gene therapy delivers bonus results
| | Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy. | | | MORE ARTICLES
|
| |
| The what, who and why of stem cells in ophthalmology: Part 1
| | Ophthalmic blogger, Irv Arons writes a tell all on what stem cells are all about, who's involved, who they are collaborating with, what type of stem cells they are using and what diseases they are aimed at. | | | A vision for the world
| | Helping others to help themselves | |
| | The ideal drop through the eyes of doctors and patients
| | Five steps and the criteria for success, as seen through the eyes of patients and their doctors... | | | Contact induced dry eye
| | Understanding the problems of contact lens induced dry eye | | | OTE at the WOC
| | The Ophthalmology TImes Europe team is looking forward to meeting many readers and customers at the Congress and to bringing you coverage of the event and new developments emerging from it. | | | Standardizing trauma terminology
| | A standardized language of trauma classification can have value for prognosis as well as description, according to Dr Dante Pieramici. | | | Flying eye hospital gets new aeroplane
| | Orbis International, an international nonprofit humanitarian organization which operates the world"s only Flying Eye Hospital, is to upgrade from a DC-10-10 to a DC-10 Series 30 freighter airline, giving the project an extra 20 years of flying time. | | | Should tear dysfunction be treated with nutritional supplements?
| | Nutritional supplements seem to make sense as a treatment of tear dysfunction, according to Marian Macsai, MD. Dr Macsai tempered her assertion with the observation that no objective trials have been performed to support the use of nutritional supplements in patients with tear deficiency. | | | Minimally invasive strabismus surgery vs the limbal approach
| | As with all medical disciplines, the goal of every surgeon is to perform surgery that is minimally invasive, in order to reduce the risk of unwanted complications and a poor postoperative appearance, and to increase patient comfort and satisfaction. | | | MORE ARTICLES
|
| |
| Anterior and posterior capsulorhexis in children
| | Anterior and posterior capsulorhexis in children | | | A clinical conundrum
| | According to the J Pediatr Ophthalmol Strabismus 2009;46:238-240 optic disc oedema is a clinical conundrum which has potential to delay diagnosis and therefore treatment of idiopathic intracranial hypertension. | | | Paediatric ophthalmology conference programme
| | The Egyptian Group of Paediatric Eye Surgery (EGPES) will be hosting the 4th International Symposium of Paediatric Ophthalmology, from 4th to 6th of November 2009, in Alexandria, Egypt. | | | Link between ROP and haemangioma in low birth-weight infants discovered
| | In infants with birth weights of 1250 g, haemangiomas are associated with the development of retinopathy of prematurity (ROP), according to study data published in the March 2009 issue of Pediatrics. | | | US introduces law protecting children's vision
| | The Vision Care for Kids Bill of 2009, legislation to provide vision care to children without health insurance, has been introduced in the US after being approved both by the Senate and by the House of Representatives. | | | Treating paediatric glaucoma
| | Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology. | | | | Long-term treatment of strabismus with Botox
| | A long-term course of injections of botulinum toxin ("Botox") offers a viable treatment for complicated strabismus, according to study results published in the December 2008 issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus. | | | Giving sight to the developing world
| OTE's Victoria Farrell interviews Cambodian paediatric ophthalmologist Phara Khauv to find out how an ORBIS initiative has impacted his practice in a vastly underserved country. | | | Good VA means good stereopsis in children
| | Postoperative visual acuity (VA) is the factor with the most significant impact on stereopsis in paediatric unilateral pseudophakic subjects, according to study results published online ahead of print by the British Journal of Ophthalmology. | | | MORE ARTICLES
|
| |
| New frontiers in IOL power calculations
| | Following a premium IOL implantation it is now possible to maintain the target refractive error of 0.5 D but errors can still arise in the calculation of the desired IOL power. Modernizing formulae may help to reduce prediction error in IOL power calculations. | | | Optical Biometry
| | Dr Paul-Rolf Preussner discusses how additional optical measurements are required to improve the accuracy limits in IOL calculation | | | IOL power: Quo vadis?
| | Increasing levels of expectations of refractive results is challenging IOL power calculations, reveals Dr Oliver Findl | | | Laser capsulotomy yields predictability
| | An investigational femtosecond laser-assisted cataract surgery system for capsulotomy creation was evaluated in a randomized, fellow eye control study. | | | Debate: Best appraoch to thin cornea
| | Refractive specialists weigh in with views on surface ablation versus the flap-based procedure. | | | Be aware of potential IOL complications
| | The potential complications associated with implantation of phakic IOLs may give cataract surgeons a few challenges, but problems can often be averted with proper sizing and vaulting. | | | Multifocality in cataract surgery
| | Dr Zaluski examines the visual performance and ascertains the level of patient satisfaction with the multifocalDiffractiva Diff-s IOL | | | Review of the year 2010
| | A review of the year in cataract & refractive, retina and glaucoma. Shows three industry experts view on their highs of the year and the changes they've experienced as well as what the future holds for 2011 | | | Femtosecond facilitates 'big bubble'
| | A new variation of femtosecond laser-assisted 'big bubble' deep anterior lamellar keratoplasty uses the laser to create an intrastromal channel serves as a pathway for the insertion of the air injection | | | MORE ARTICLES
|
| |
| Light adjustable lenses offer stability of refraction
| | Residual myopic errors can be successfully corrected postoperatively by using light-adjustable lens technology (LAL) in cataract patients, concludes a study published online by Ophthalmology. | | | ICLs effective over long-periods
| | The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology. | | | Presbyopia lens launch
| | Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology. | | | IOL receives further $40 million investment
| | Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe. | | | New offerings for the refractive surgeon
| | The Visante omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care. | | | Can violent games improve lazy eyes?
| | Scientists at New York's Rochester University say that playing violent video games may improve contrast sensitivity, which is often impaired by amblyopia. | | | Eye diseases in pre-school children more common than first thought
| | In what is believed to be the first comprehensive eye disease study among urban pre-schoolers, investigators writing in the April issue of the journal Ophthalmology report that while vision problems are rare, they are more common than once thought. | | | Advantages of aspheric aberration-free method
| | Patients in need of visual corrections whose vision is not affected by existing high-order aberrations (HOAs) may have an alternative to wavefront treatment using an aberration-free method. | | | Building artificial corneas
| | Insights gained from research into keratoconus using extremely intense x-rays could refine laser surgeries, including LASIK, and may one day even lead to the development of an artificial cornea, according to researchers at Cardiff University, UK. | | | MORE ARTICLES
|
| |
| |
| Advanced Retinal Therapy
| | Advanced Retinal Therapy will be held in Vienna, Austria on 3 December 2011. At this event updates, trends and controversies in retinal tehrapy will be discussed in symposia, key-note lectures and a panel discussion session. | | | Ozurdex recommended for treating macular oedema
| The National Institute for Health and Clinical Excellence (NICE) has recommended Ozurdex for the treatment of macular oedema caused by central retinal vein occlusion (CRVO). | | | Anticoagulant poses higher risk for post- bleeding in VRS
| | Anticoagulation (warafin) therapy was linked to a higher risk of post vitreoretinal surgery (VRS) bleeding in comparison with antipletelet (aspirin, clopidogrel) therapy vitreoretinal. | | | Ranibizumab injections in combination with laser therapy offers new treatment for DME
| | The Diabetic Retinopathy Clinical Research Network (DRCR.net) study, published in Ophthalmology online has shown that ranibizumab (Lucentis) injections, in combination with laser treatment has produced better vision results than in patients treated by laser alone for diabetic macular oedema (DME). | | | Gene genie for AMD and RP?
| | Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina. | | | New retinal navigation system gains approval
| | The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval. | | | Two Phase III Lucentis studies show promise for RVO
| | Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting. | | | Cataract surgery in patients with pre-existing AMD: Risks and Benefits
| | Cataract surgery in patients with pre-existing AMD: Risks and Benefits | | | A review of the role and efficacy of anti-VEGF therapy in macular disease
|
| A review of the role and efficacy of anti-VEGF therapy in macular disease | | | MORE ARTICLES
|
| |
| |
|
|
| 
